Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement.

Pharmaceutics · 2023 · PMC10534762 · PMID 37765307

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

AUC 0→24 of RIS-HA-TCS-mPEG was found to be 2299.53μg/mL*h, which was highly significant compared to RIS-HA-TCS’s AUC 0→24 (1366.08 μg/mL*h), marketed preparation’s AUC 0→24 (893.52 μg/mL*h) and RIS suspension’s AUC 0→24 (266.67μg/mL*h).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.